Compared side by side

CagriSema vs tirzepatide: how they differ

Reviewed How we check the libraryPublished by PepVault

The short answer

Both are weekly shots that pair GLP-1 with a second hormone: CagriSema combines semaglutide (GLP-1) with cagrilintide, an amylin analogue, and tirzepatide is one molecule that activates the GLP-1 and GIP receptors. Tirzepatide is FDA-approved, as Mounjaro and Zepbound; CagriSema isn’t approved yet, and Novo Nordisk filed it with the FDA in December 2025. In their own trials, CagriSema averaged about 20% weight loss at 68 weeks, and tirzepatide’s 15 mg up to 22.5% at 72 weeks (SURMOUNT-1).

Side by side

ComparedCagriSemaTirzepatide
CategoryMetabolic & GLP-1Metabolic & GLP-1
Also known asCagrilintide/semaglutide, Cagrilintide-semaglutide, Cagri-Sema, Cagri + SemaMounjaro, Zepbound, LY3298176
What it isTwo weekly drugs in one regimen: cagrilintide, a long-acting version of the fullness hormone amylin, and semaglutide, the GLP-1 drug in Wegovy and Ozempic.The first dual GIP/GLP-1 receptor agonist: it activates two gut-hormone pathways at once, and in a head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks).
How it worksWeekly combination of two long-acting hormone analogues: cagrilintide, an amylin analogue that acts on amylin and calcitonin receptors, and semaglutide, a GLP-1 receptor agonist. Amylin and GLP-1 curb appetite through partly different brain pathways, so their effects add up: in REDEFINE 1 the pair lost more weight than either drug alone. Doses are written per component (2.4 mg/2.4 mg is 2.4 mg of each). Not approved: Novo Nordisk filed it with the FDA in December 2025, and a decision is expected in the fourth quarter of 2026.Dual GIP/GLP-1 receptor agonist. Significantly reduces body weight through appetite suppression, slowed gastric emptying, and improved insulin sensitivity. Approved for T2DM and obesity management.
Commonly reportedStrong appetite suppression and early fullness, with nausea, vomiting or constipation through the dose steps. In its main trial people lost about 20% of body weight on average at 68 weeks, more than on semaglutide alone; it is not approved yet.Very strong appetite suppression and meals ending early, with nausea or tiredness for a day or two after the injection, mostly after dose increases. FDA-approved for diabetes (Mounjaro) and for weight management and sleep apnea (Zepbound).
Studied rangeResearch range: 0.25–2.4 mg, starting dose 0.25 mg. Studied in research — not a recommendation.FDA label: 2.5–15 mg, starting dose 2.5 mg.
How oftenWeeklyWeekly
Half-life~1 week for each component (measured in people: cagrilintide 159–195 hours and semaglutide 145–165 hours in a phase 1b trial)~5 days (FDA label)
RouteSubQ injectionSubQ injection
Typical runStudied as an ongoing weekly treatment: 68 to 84 weeks in phase 3. Not approved yet; Novo Nordisk filed for US approval in December 2025.FDA-approved for ongoing use. Titrate slowly upward. Community maintains on minimum effective dose.
EvidenceEstablished: clinical trials or FDA-approved use existsEstablished: clinical trials or FDA-approved use exists
Common side effectsNausea, vomiting, diarrhea, constipation, abdominal painNausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue

Typical run: Community practice — opinions vary. Not a clinical recommendation.

A smiling man in a grey t-shirt in his living room, holding his phone

Model. Individual results vary.

PepVault for iPhone

Taking CagriSema or tirzepatide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

CagriSema

  • Day 1–28 · 0.25 mg The 0.25 mg start
  • Day 29–364 · 0.5 mg 0.5 mg of each
  • Day 57–364 · 1 mg 1 mg of each, halfway up
  • Day 85–364 · 1.7 mg 1.7 mg of each, one step from the top
  • Day 113+ · 2.4 mg 2.4 mg/2.4 mg, the maintenance dose

Every card for CagriSema, with its sources

Tirzepatide

  • Day 1–28 · 2.5 mg Getting your gut acclimated
  • Day 29–56 · 5 mg First therapeutic dose — weight drops
  • Day 57–112 · 7.5 mg Dual agonism in full effect
  • Day 113–168 · 12.5 mg Max titration reached
  • Day 169–504 Weeks 24 to 72: where most people plateau
  • Day 365+ A maintenance medication, not a course

Every card for tirzepatide, with its sources

Questions people ask

How long do CagriSema and tirzepatide last?

The half-life of CagriSema is ~1 week for each component (measured in people: cagrilintide 159–195 hours and semaglutide 145–165 hours in a phase 1b trial). The half-life of tirzepatide is ~5 days (FDA label).

How often are CagriSema and tirzepatide taken?

CagriSema: weekly. Route: SubQ injection. Tirzepatide: weekly. Route: SubQ injection.

How are CagriSema and tirzepatide dosed in research?

The research range for CagriSema is 0.25–2.4 mg, with a 0.25 mg starting dose. Studied in research — not a recommendation. The FDA label range for tirzepatide is 2.5–15 mg, with a 2.5 mg starting dose.

What are the common side effects of CagriSema and tirzepatide?

For CagriSema, the library lists: nausea, vomiting, diarrhea, constipation, abdominal pain. For tirzepatide: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue.

Each one in full

Track it in the app

PepVault for iPhone

Taking CagriSema or tirzepatide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo